Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics (Nasdaq: ABEO) has granted equity awards to five new non-executive employees as employment inducement. The awards, approved under Nasdaq Listing Rule 5635(c)(4), consist of a total of 28,600 restricted shares of common stock. The shares will vest in three equal annual installments, with full vesting occurring on the third anniversary of the Grant Date, contingent upon continued employment. The Compensation Committee of Abeona's Board of Directors approved these awards on December 30, 2024.
Abeona Therapeutics (Nasdaq: ABEO) ha concesso premi azionari a cinque nuovi dipendenti non esecutivi come incentivo all'assunzione. I premi, approvati secondo la Regola di Quotazione 5635(c)(4) di Nasdaq, consistono in un totale di 28.600 azioni riservate di azioni ordinarie. Le azioni matureranno in tre rate annuali uguali, con la vestizione completa che avverrà al terzo anniversario della Data di Concessione, subordinatamente al mantenimento dell'impiego. Il Comitato per le Compensazioni del Consiglio di Amministrazione di Abeona ha approvato questi premi il 30 dicembre 2024.
Abeona Therapeutics (Nasdaq: ABEO) ha concedido premios en acciones a cinco nuevos empleados no ejecutivos como incentivo para la contratación. Los premios, aprobados bajo la Regla de Cotización 5635(c)(4) de Nasdaq, consisten en un total de 28,600 acciones restringidas de acciones comunes. Las acciones se adquirirán en tres cuotas anuales iguales, con la adquisición completa ocurriendo en el tercer aniversario de la Fecha de Concesión, condicionado a la continuación del empleo. El Comité de Compensación de la Junta Directiva de Abeona aprobó estos premios el 30 de diciembre de 2024.
아베오나 테라퓨틱스 (나스닥: ABEO)는 고용 유인을 위해 5명의 신입 비상근 직원을 대상으로 주식 보상을 제공했습니다. 이러한 보상은 나스닥 상장 규칙 5635(c)(4)에 따라 승인되었으며, 총 28,600주의 제한주식으로 구성됩니다. 주식은 3년마다 동일한 비율로 분할되어 부여되며, 전체 부여는 부여일의 3주년이 되는 날에 이루어지며, 계속 고용되는 조건입니다. 아베오나의 보상위원회는 2024년 12월 30일에 이 보상을 승인했습니다.
Abeona Therapeutics (Nasdaq: ABEO) a accordé des indemnités en actions à cinq nouveaux employés non exécutifs en tant qu'incitatif à l'embauche. Les indemnités, approuvées conformément à la Règle de Cotation Nasdaq 5635(c)(4), comprennent un total de 28 600 actions restreintes d'actions ordinaires. Les actions seront acquises en trois versements annuels égaux, avec une acquisition complète qui se produira au troisième anniversaire de la Date d'Octroi, sous réserve de la poursuite de l'emploi. Le Comité de Rémunération du Conseil d'Administration d'Abeona a approuvé ces indemnités le 30 décembre 2024.
Abeona Therapeutics (Nasdaq: ABEO) hat fünf neuen nicht-executive Mitarbeitern Aktienvergütungen als Einstellungsanreiz gewährt. Die Vergütungen, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt wurden, bestehen aus insgesamt 28.600 eingeschränkten Aktien stammenden von Stammaktien. Die Aktien verfallen in drei gleichen jährlichen Raten, wobei die vollständige Gewährung am dritten Jahrestag des Zuschreibungsdatums erfolgt, vorausgesetzt, das Arbeitsverhältnis bleibt bestehen. Der Vergütungsausschuss des Vorstands von Abeona genehmigte diese Vergütungen am 30. Dezember 2024.
- Successful attraction of new talent with equity-based compensation
- Three-year vesting schedule promotes employee retention
- Potential dilution of existing shareholders through new share issuance
CLEVELAND, , Dec. 31, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On December 30, 2024, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 28,600 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of the FDA’s review of our BLA resubmission for pz-cel; the FDA’s grant of a Priority Review Voucher upon pz-cel approval; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
FAQ
How many restricted shares did Abeona Therapeutics (ABEO) grant to new employees in December 2024?
What is the vesting schedule for ABEO's December 2024 employee equity awards?
How many new employees received ABEO's equity awards in December 2024?
Under which Nasdaq rule were ABEO's December 2024 equity awards approved?
